 |
IRVINE, CaliforniaMay 29, 2026 /PRNewswire/ — PeproMene Bio, Inc. today announced that the latest clinical data from its ongoing Phase 1 study evaluating PMB-CT01, an investigational CAR T cell therapy targeting B-cell activating factor receptor (BAFF-R), has been selected for an oral presentation at the European Hematology Association (EHA) 2026 Congress.
Among the nine patients treated in this phase, PMB-CT01 demonstrated a favorable safety profile, with no dose-limiting toxicities, no cytokine release syndrome (CRS) of Grade 2 or higher, and no immune effector cell-associated neurotoxicity syndrome (ICANS) of Grade 2 or higher. Seven of the nine patients (78%) achieved a complete response (CR). As of the latest data cutoff, no patients had relapsed, and responses were ongoing, with the longest duration exceeding three years. Patients who achieved responses also attained minimal residual disease (MRD)-negative status, indicating deep responses with no detectable residual cancer cells.
Based on these results, the trial is actively enrolling patients in expansion cohorts for mantle cell lymphoma, large B-cell lymphoma, and follicular lymphoma (FL). Importantly, the first patient treated in this expansion phase, a patient with transformed FL (tFL) who had progressed after prior CD19 CAR T therapy, achieved a complete response at the first disease assessment. tFL is an aggressive lymphoma with currently limited established treatment options.
“Patients face a significant unmet medical need when cancer progresses after prior CD19 CAR T therapy, with very limited subsequent treatment options,” said Dr. Larry W. Kwak, Scientific Founder of PeproMene Bio. “These durable complete responses clinically validate the potential of BAFF-R as a novel target, and the favorable safety profile observed to date may support its future use in community oncology outpatient settings and further exploration of its potential in refractory autoimmune diseases.”
Presentation Details
Abstract Title: BAFF-R CAR T Cells (PMB-CT01) Demonstrate Durable Efficacy and Favorable Safety in Patients with Relapsed/Refractory B-Cell Lymphoma Who Failed Prior CD19-Targeted Therapy or Are CD19-Negative
Abstract: EHA-1611 S287
Date/Time: June 14, 11:00 AM to 12:15 PM CEST
Presenter: Larry W. Kwak, MD, PhD
About PMB-CT01
PMB-CT01 is a first-in-class BAFF-R-targeted autologous CAR T cell therapy currently being evaluated in Phase 1 trials for relapsed/refractory B-NHL and relapsed/refractory B-ALL. BAFF-R is expressed almost exclusively on B cells and is critical for B cell survival, thereby reducing the likelihood of tumor escape due to antigen loss.
About PeproMene Bio
Forward-Looking Statements
This press release contains forward-looking statements subject to risks and uncertainties, including those related to clinical development, regulatory outcomes, therapeutic potential, and commercialization. Unless otherwise required by law, PeproMene Bio, Inc. undertakes no obligation to update forward-looking statements.